Selected research
Industry Research
lrinotecan Industry Research Report 2026
Market perspective
The global lrinotecan market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for lrinotecan is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for lrinotecan is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for lrinotecan is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of lrinotecan include Actiza Pharmaceutical, Cipla, Getwell, Salius, Taj Pharma, West-ward Pharmaceuticals, Pfizer and Teva, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global lrinotecan market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
lrinotecan Market by Company
Actiza Pharmaceutical
Cipla
Getwell
Salius
Taj Pharma
West-ward Pharmaceuticals
Pfizer
Teva
lrinotecan Segment by Type
Irinotecan Hydrochloride Injection 40mg
Irinotecan Hydrochloride Injection 100mg
Others
lrinotecan Segment by Application
Clinic
Hospital
Others
lrinotecan Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global lrinotecan market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of lrinotecan and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of lrinotecan.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of lrinotecan manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of lrinotecan by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of lrinotecan in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Irinotecan Hydrochloride Injection 40mg
- Irinotecan Hydrochloride Injection 100mg
- Others
Applications
- Clinic
- Hospital
- Others
Companies covered
- Actiza Pharmaceutical
- Cipla
- Getwell
- Salius
- Taj Pharma
- West-ward Pharmaceuticals
- Pfizer
- Teva
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global lrinotecan Market Size (2021-2032)
- 2.2.2 Global lrinotecan Sales (2021-2032)
- 2.2.3 Global lrinotecan Market Average Price (2021-2032)
- 2.3 lrinotecan by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Irinotecan Hydrochloride Injection 40mg
- 2.3.3 Irinotecan Hydrochloride Injection 100mg
- 2.3.4 Others
- 2.4 lrinotecan by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Clinic
- 2.4.3 Hospital
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global lrinotecan Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global lrinotecan Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global lrinotecan Revenue of Manufacturers (2021-2026)
- 3.4 Global lrinotecan Average Price by Manufacturers (2021-2026)
- 3.5 Global lrinotecan Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of lrinotecan, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of lrinotecan, Product Type & Application
- 3.8 Global Manufacturers of lrinotecan, Established Date
- 3.9 Global lrinotecan Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Actiza Pharmaceutical
- 4.1.1 Actiza Pharmaceutical Company Information
- 4.1.2 Actiza Pharmaceutical Business Overview
- 4.1.3 Actiza Pharmaceutical lrinotecan Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Actiza Pharmaceutical lrinotecan Product Portfolio
- 4.1.5 Actiza Pharmaceutical Recent Developments
- 4.2 Cipla
- 4.2.1 Cipla Company Information
- 4.2.2 Cipla Business Overview
- 4.2.3 Cipla lrinotecan Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Cipla lrinotecan Product Portfolio
- 4.2.5 Cipla Recent Developments
- 4.3 Getwell
- 4.3.1 Getwell Company Information
- 4.3.2 Getwell Business Overview
- 4.3.3 Getwell lrinotecan Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Getwell lrinotecan Product Portfolio
- 4.3.5 Getwell Recent Developments
- 4.4 Salius
- 4.4.1 Salius Company Information
- 4.4.2 Salius Business Overview
- 4.4.3 Salius lrinotecan Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Salius lrinotecan Product Portfolio
- 4.4.5 Salius Recent Developments
- 4.5 Taj Pharma
- 4.5.1 Taj Pharma Company Information
- 4.5.2 Taj Pharma Business Overview
- 4.5.3 Taj Pharma lrinotecan Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Taj Pharma lrinotecan Product Portfolio
- 4.5.5 Taj Pharma Recent Developments
- 4.6 West-ward Pharmaceuticals
- 4.6.1 West-ward Pharmaceuticals Company Information
- 4.6.2 West-ward Pharmaceuticals Business Overview
- 4.6.3 West-ward Pharmaceuticals lrinotecan Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 West-ward Pharmaceuticals lrinotecan Product Portfolio
- 4.6.5 West-ward Pharmaceuticals Recent Developments
- 4.7 Pfizer
- 4.7.1 Pfizer Company Information
- 4.7.2 Pfizer Business Overview
- 4.7.3 Pfizer lrinotecan Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Pfizer lrinotecan Product Portfolio
- 4.7.5 Pfizer Recent Developments
- 4.8 Teva
- 4.8.1 Teva Company Information
- 4.8.2 Teva Business Overview
- 4.8.3 Teva lrinotecan Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Teva lrinotecan Product Portfolio
- 4.8.5 Teva Recent Developments
5 Global lrinotecan Market Scenario by Region
- 5.1 Global lrinotecan Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global lrinotecan Sales by Region: 2021-2032
- 5.2.1 Global lrinotecan Sales by Region: 2021-2026
- 5.2.2 Global lrinotecan Sales by Region: 2027-2032
- 5.3 Global lrinotecan Revenue by Region: 2021-2032
- 5.3.1 Global lrinotecan Revenue by Region: 2021-2026
- 5.3.2 Global lrinotecan Revenue by Region: 2027-2032
- 5.4 North America lrinotecan Market Facts & Figures by Country
- 5.4.1 North America lrinotecan Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America lrinotecan Sales by Country (2021-2032)
- 5.4.3 North America lrinotecan Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe lrinotecan Market Facts & Figures by Country
- 5.5.1 Europe lrinotecan Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe lrinotecan Sales by Country (2021-2032)
- 5.5.3 Europe lrinotecan Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific lrinotecan Market Facts & Figures by Country
- 5.6.1 Asia Pacific lrinotecan Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific lrinotecan Sales by Country (2021-2032)
- 5.6.3 Asia Pacific lrinotecan Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America lrinotecan Market Facts & Figures by Country
- 5.7.1 South America lrinotecan Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America lrinotecan Sales by Country (2021-2032)
- 5.7.3 South America lrinotecan Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa lrinotecan Market Facts & Figures by Country
- 5.8.1 Middle East and Africa lrinotecan Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa lrinotecan Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa lrinotecan Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global lrinotecan Sales by Type (2021-2032)
- 6.1.1 Global lrinotecan Sales by Type (2021-2032) & (k units)
- 6.1.2 Global lrinotecan Sales Market Share by Type (2021-2032)
- 6.2 Global lrinotecan Revenue by Type (2021-2032)
- 6.2.1 Global lrinotecan Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global lrinotecan Revenue Market Share by Type (2021-2032)
- 6.3 Global lrinotecan Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global lrinotecan Sales by Application (2021-2032)
- 7.1.1 Global lrinotecan Sales by Application (2021-2032) & (k units)
- 7.1.2 Global lrinotecan Sales Market Share by Application (2021-2032)
- 7.2 Global lrinotecan Revenue by Application (2021-2032)
- 7.2.1 Global lrinotecan Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global lrinotecan Revenue Market Share by Application (2021-2032)
- 7.3 Global lrinotecan Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 lrinotecan Value Chain Analysis
- 8.1.1 lrinotecan Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 lrinotecan Production Mode & Process
- 8.2 lrinotecan Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 lrinotecan Distributors
- 8.2.3 lrinotecan Customers
9 Global lrinotecan Analyzing Market Dynamics
- 9.1 lrinotecan Industry Trends
- 9.2 lrinotecan Industry Drivers
- 9.3 lrinotecan Industry Opportunities and Challenges
- 9.4 lrinotecan Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst